Individuals HIV-1-Infected and HIV-1-Uninfected T Cell Memory

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Cooperation of TNF Family Members CD40 Ligand, Receptor Activator of NF- κB Ligand, and TNF- α in the Activation of Dendritic Cells and the Expansion of Viral This information is current as Specific CD8+ T Cell Memory Responses in of September 24, 2021. HIV-1-Infected and HIV-1-Uninfected Individuals Qigui Yu, Jenny X. Gu, Colin Kovacs, John Freedman, Elaine K. Thomas and Mario A. Ostrowski Downloaded from J Immunol 2003; 170:1797-1805; ; doi: 10.4049/jimmunol.170.4.1797 http://www.jimmunol.org/content/170/4/1797 http://www.jimmunol.org/ References This article cites 36 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/170/4/1797.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Cooperation of TNF Family Members CD40 Ligand, Receptor Activator of NF-␬B Ligand, and TNF-␣ in the Activation of Dendritic Cells and the Expansion of Viral Specific CD8؉ T Cell Memory Responses in HIV-1-Infected and HIV-1-Uninfected Individuals1 Qigui Yu,* Jenny X. Gu,* Colin Kovacs,* John Freedman,† Elaine K. Thomas,‡ and Mario A. Ostrowski2*† Members of the TNF superfamily have been shown to be instrumental in enhancing cell-mediated immune responses, primarily Downloaded from through their interactions with dendritic cells (DCs). We systematically evaluated the ability of three TNF superfamily molecules, CD40 ligand (CD40L), receptor activator of NF-␬B ligand (RANKL), and TNF-␣, to expand ex vivo EBV-specific CTL responses in healthy human individuals and ex vivo HIV-1-specific CTL responses in HIV-1-infected individuals. In both groups of indi- viduals, we found that all three TNF family molecules could expand CTL responses, albeit at differing degrees. CD40L treatment alone was better than RANKL or TNF-␣ alone to mature DCs and to expand CTL. In healthy volunteers, TNF-␣ or RANKL could cooperate with CD40L to maximize the ability of DCs to expand virus-specific CTL responses. In HIV-1 infection, cooperative http://www.jimmunol.org/ effects between TNF-␣ or RANKL in combination with CD40L were variable. TNF-␣ and RANKL cooperated with CD40L via differing mechanisms, i.e., TNF-␣ enhanced IL-12 production, whereas RANKL enhanced survival of CD40L-stimulated DCs. These findings demonstrate that optimal maturation of DCs requires multiple signals by TNF superfamily members that include CD40L. In HIV-1 infection, DCs may only require CD40L to maximally expand CTL. Finally, CTL responses were higher in CD4؉ T cell-containing conditions even in the presence of TNF family molecules, suggesting that CD4؉ T cells can provide help .to CD8؉ T cells independently of CD40L, RANKL, or TNF-␣. The Journal of Immunology, 2003, 170: 1797–1805 ϩ vigorous and sustained CD8 T cell cytotoxic (CTL) tion and activation (12, 13), as manifested by the increased surface by guest on September 24, 2021 response in the host is required to control infections expression of MHC class I and II molecules, the costimulatory A caused by persistent viruses such as lymphocytic cho- molecules CD80 (B7-1) and CD86 (B7-2), and the adhesion mol- riomeningitis virus, CMV, EBV, and possibly HIV-1 and SIV (1– ecules CD54 (ICAM-1) and CD58 (LFA-30). In addition, CD40 ϩ 7). In this regard, CD4 T cell help has been shown to be instru- ligation of mature DCs stimulates the production of proinflamma- mental in maintaining effective CTL memory responses, through at tory cytokines IL-1, IL-6, and TNF-␣, and T cell growth and dif- ϩ least two ways. In murine models, activated Ag-specific CD4 T ferentiation factors, IL-12 and IL-15, as well as increasing DC cells have been shown to help CTL by local IL-2 production and survival (12, 14–20). These phenotypic changes confer an en- more importantly through the expression of CD40 ligand hanced capacity of DCs to induce CD8ϩ T cell proliferation and 3 (CD40L) (8–11). CD40L is a type II membrane protein of the cytotoxicity. Thus, CD4ϩ T cells help CTL responses via their ϩ TNF superfamily predominantly expressed on activated CD4 T effects on DC activation and maturation. cells. CD40 is constitutively expressed on immature dendritic cells Other members of the TNF receptor/ligand superfamily have (DCs), and CD40 ligation of immature DCs induces their matura- also been proposed to play a role in either enhancing or bypassing CD4ϩ T cell help in eliciting potent antiviral CTL responses. The receptor activator of NF-␬B ligand (RANKL)-RANK (also called *Clinical Sciences Division, University of Toronto, Toronto, Canada; †St. Michael’s TRANCE (TNF-related activation-induced cytokine)-TRANCE Hospital, University of Toronto, Toronto, Canada; and ‡Immunex Corporation, Se- attle, WA 98101 receptor) pathway has recently been shown in murine models to Received for publication May 17, 2002. Accepted for publication December 6, 2002. have similar functions to that of the CD40L-CD40 pathway in the ϩ The costs of publication of this article were defrayed in part by the payment of page generation of antiviral CD4 T-specific immune responses (21– charges. This article must therefore be hereby marked advertisement in accordance 23). RANKL is a member of the TNF superfamily sharing greatest with 18 U.S.C. Section 1734 solely to indicate this fact. amino acid similarity (28%) with CD40L (CD154). RANKL is 1 This study was funded through grant support supplied by American Foundation for expressed on both activated CD4ϩ T and CD8ϩ T cells (24). AIDS Research and Aventis-Pasteur. Q.Y. and M.A.O. are career scientists of The Ontario HIV Treatment Network. RANK, the receptor for RANKL, is constitutively expressed on DCs (22); however, RANK expression is greater on mature DCs or 2 Address correspondence and reprint requests to Dr. Mario A. Ostrowski, Clinical Sciences Division, Room 6271, Medical Sciences Building, University of Toronto, on CD40-ligated DCs (24). Similar to CD40L, conditioning of Toronto, Ontario, Canada, M5S 1A8. E-mail address: [email protected] murine DCs with RANKL has been shown to elicit production of 3 Abbreviations used in this paper: CD40L, CD40 ligand; B-LCL, B-lymphoblastoid proinflammatory cytokines, IL-1 and IL-6, and T cell growth and cell line; CD40LT, trimeric CD40L; DC, dendritic cell; iMDDC, immature MDDC; MDDC, monocyte-derived DC; RANK, receptor activator of NF-␬B; RANKL, differentiation factors, IL-12 and IL-15. RANKL also dramatically RANK ligand; RANKLT, trimeric RANKL. inhibits DC apoptosis via increased Bcl-xL expression (22–25). Copyright © 2003 by The American Association of Immunologists, Inc. 0022-1767/03/$02.00 1798 COOPERATION BETWEEN CD40L, RANKL, AND TNF-␣ RANKL, however, does not markedly up-regulate DC surface ex- Generation of MDDCs, cell cultures, and stimulation pression of MHC molecules, costimulatory molecules (CD80 and MDDCs were generated by a modification of a method previously de- CD86), CD40, or adhesion molecules (CD54), which is observed scribed (19, 30). Briefly, PBMCs obtained by the Ficoll-Paque gradient with CD40L conditioning. It has been postulated that the primary centrifugation (Amersham Pharmacia Biotech, Uppsala, Sweden) were effect of RANKL on DCs is by enhancing DC survival in tissues, separated on multistep Percoll gradients (Sigma-Aldrich, St. Louis, MO). thus allowing greater opportunity for DCs to prime T cells (26). The recovered monocytes were depleted of contaminating B cells, T cells, NK cells, and granulocytes using Ab-conjugated magnetic beads from the The role of the RANKL-RANK pathway in induction of murine or Monocyte Negative Isolation Kit (Dynal, Oslo, Norway). Purified mono- human CTL responses, however, has not yet been evaluated. cytes were cultured at 1 ϫ 106 cells/ml in medium consisting of RPMI TNF-␣ is produced and secreted early in the inflammatory re- 1640 plus 10% FCS, 2 mM glutamine, 25 mM HEPES, and antibiotics in sponse by activated monocytes, NK cells, and Th1 T cells. TNF-␣ the presence of 50 ng/ml human rGM-CSF and 100 ng/ml human rIL-4 ϩ (PeproTech, Rocky Hill, NJ). GM-CSF and IL-4 were added again on days has been shown to differentiate CD34 progenitor cells into DCs. 3 and 5 with the fresh complete RPMI 1640 medium. After 7 days of In addition, TNF-␣ has been shown to up-regulate adhesion and culture, more than 50% of the cells were CD1ahigh, MHC class IIϩ, costimulatory molecules of immature monocyte-derived DCs CD80low, and CD14Ϫ, which represents an immature DC phenotype. The (iMDDCs), but not to the extent as that seen with CD40L (14). immature DCs were then aliquoted and cultured for 72 h in the following Thus, DC activation and maturational signals can originate from conditions: 1) medium alone; 2) soluble recombinant human trimeric CD40L (CD40LT) at 1 ␮g/ml; 3) soluble recombinant human trimeric multiple sources. The relative importance of each of these signals, RANKL (RANKLT) at a final concentration of 1 ␮g/ml (CD40LT and either alone or in combination, has not been systematically eval- RANKLT were obtained as a gift from Immunex, Seattle, WA); 4) soluble uated, although knowledge of this would be important for vaccine human rTNF-␣ at a final concentration of 10 ng/ml (PeproTech); 5) ϩ ϩ ␣ ϩ ␣ design.
Recommended publications
  • RANKL As a Novel EMT Marker 858 Cell Research (2008) 18:858-870

    RANKL As a Novel EMT Marker 858 Cell Research (2008) 18:858-870

    npg RANKL as a novel EMT marker 858 Cell Research (2008) 18:858-870. npg © 2008 IBCB, SIBS, CAS All rights reserved 1001-0602/08 $ 30.00 ORIGINAL ARTICLE www.nature.com/cr Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells Valerie A Odero-Marah1, Ruoxiang Wang1, Gina Chu1, Majd Zayzafoon2, Jianchun Xu1, Chunmeng Shi1, Fray F Marshall1, Haiyen E Zhau1, Leland WK Chung1 1Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, NE, Atlanta, GA 30322, USA; 2Department of Pathology, University of Alabamn, Birmingham, AL 35294, USA Epithelial-mesenchymal transition (EMT) in cancer describes the phenotypic and behavioral changes of cancer cells from indolent to virulent forms with increased migratory, invasive and metastatic potential. EMT can be induced by soluble proteins like transforming growth factor β1 (TGFβ1) and transcription factors including Snail and Slug. We uti- lized the ARCaPE/ARCaPM prostate cancer progression model and LNCaP clones stably overexpressing Snail to identify novel markers associated with EMT. Compared to ARCaPE cells, the highly tumorigenic mesenchymal ARCaPM and ARCaPM1 variant cells displayed a higher incidence of bone metastasis after intracardiac administration in SCID mice. ARCaPM and ARCaPM1 expressed mesenchymal stromal markers of vimentin and N-cadherin in addition to elevated levels of Receptor Activator of NF-κB Ligand (RANKL). We observed that both epidermal growth factor (EGF) plus TGFβ1 treatment and Snail overexpression induced EMT in ARCaPE and LNCaP cells, and EMT was associated with increased expression of RANKL protein.
  • RANK Interaction and Signaling − RANKL Structural and Functional

    RANK Interaction and Signaling − RANKL Structural and Functional

    Structural and Functional Insights of RANKL −RANK Interaction and Signaling Changzhen Liu, Thomas S. Walter, Peng Huang, Shiqian Zhang, Xuekai Zhu, Ying Wu, Lucy R. Wedderburn, Peifu This information is current as Tang, Raymond J. Owens, David I. Stuart, Jingshan Ren and of October 1, 2021. Bin Gao J Immunol published online 14 May 2010 http://www.jimmunol.org/content/early/2010/05/14/jimmun ol.0904033 Downloaded from Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 1, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published May 14, 2010, doi:10.4049/jimmunol.0904033 The Journal of Immunology Structural and Functional Insights of RANKL–RANK Interaction and Signaling Changzhen Liu,*,†,1 Thomas S. Walter,‡,1 Peng Huang,x Shiqian Zhang,{ Xuekai Zhu,*,† Ying Wu,*,† Lucy R. Wedderburn,‖ Peifu Tang,x Raymond J. Owens,‡ David I. Stuart,‡ Jingshan Ren,‡ and Bin Gao*,†,‖ Bone remodeling involves bone resorption by osteoclasts and synthesis by osteoblasts and is tightly regulated by the receptor activator of the NF-kB ligand (RANKL)/receptor activator of the NF-kB (RANK)/osteoprotegerin molecular triad.
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review

    TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review

    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
  • Increased Expression of CD154 and FAS in SLE Patients’ Lymphocytes Maria Elena Manea, Ruediger B

    Increased Expression of CD154 and FAS in SLE Patients’ Lymphocytes Maria Elena Manea, Ruediger B

    Increased expression of CD154 and FAS in SLE patients’ lymphocytes Maria Elena Manea, Ruediger B. Mueller, Doru Dejica, Ahmed Sheriff, Georg Schett, Martin Herrmann, Peter Kern To cite this version: Maria Elena Manea, Ruediger B. Mueller, Doru Dejica, Ahmed Sheriff, Georg Schett, et al.. Increased expression of CD154 and FAS in SLE patients’ lymphocytes. Rheumatology International, Springer Verlag, 2009, 30 (2), pp.181-185. 10.1007/s00296-009-0933-4. hal-00568285 HAL Id: hal-00568285 https://hal.archives-ouvertes.fr/hal-00568285 Submitted on 23 Feb 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Increased expression of CD154 and FAS in SLE patients’ lymphocytes Maria Elena Manea1‡, MD, Ruediger B. Mueller2,3‡, MD, Doru Dejica1, PhD, Ahmed Sheriff2, PhD, Georg Schett2, MD, Martin Herrmann2, PhD, Peter Kern4, MD 1 Department of Immunopathology. “Iuliu Hatieganu" University of Medicine and Pharmacy, Str Croitorilor no 19-21, 3400 Cluj-Napoca, Romania. 2 Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nürnberg, Germany 3 Departement of Rheumatologie, Kantonsspital St. Gallen, Switzerland 4 Franz von Prümmer Klinik, Bahnhofstraße 16, 97769 Bad Brückenau, Germany ‡ both authors equally contributed to the work Address correspondence and reprint requests to: Ruediger B.
  • The Roadmap of RANKL/RANK Pathway in Cancer

    The Roadmap of RANKL/RANK Pathway in Cancer

    cells Review The Roadmap of RANKL/RANK Pathway in Cancer Sandra Casimiro 1,* , Guilherme Vilhais 2, Inês Gomes 1 and Luis Costa 1,3,* 1 Luis Costa Laboratory, Instituto de Medicina Molecular—João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal; [email protected] 2 Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal; [email protected] 3 Oncology Division, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (S.C.); [email protected] (L.C.) Abstract: The receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling. Targeting RANKL with the antibody denosumab is part of the standard of care for bone loss diseases, including bone metastases (BM). Over the last decade, evidence has implicated RANKL/RANK pathway in hormone and HER2-driven breast carcinogenesis and in the acquisition of molecular and phenotypic traits associated with breast cancer (BCa) aggressiveness and poor prognosis. This marked a new era in the research of the therapeutic use of RANKL inhibition in BCa. RANKL/RANK pathway is also an important immune mediator, with anti-RANKL therapy recently linked to improved response to immunotherapy in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). This review summarizes and discusses the pre-clinical and clinical evidence of the relevance of the RANKL/RANK pathway in cancer biology and therapeutics, focusing on bone metastatic disease, BCa onset and progression, and immune modulation.
  • Cell-Expressed CD154 in Germinal Centers Expression, Regulation

    Cell-Expressed CD154 in Germinal Centers Expression, Regulation

    Expression, Regulation, and Function of B Cell-Expressed CD154 in Germinal Centers Amrie C. Grammer, Richard D. McFarland, Jonathan Heaney, Bonnie F. Darnell and Peter E. Lipsky This information is current as of September 25, 2021. J Immunol 1999; 163:4150-4159; ; http://www.jimmunol.org/content/163/8/4150 Downloaded from References This article cites 74 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/163/8/4150.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Expression, Regulation, and Function of B Cell-Expressed CD154 in Germinal Centers1 Amrie C. Grammer,* Richard D. McFarland,† Jonathan Heaney,* Bonnie F. Darnell,† and Peter E. Lipsky2* Activated B cells and T cells express CD154/CD40 ligand in vitro. The in vivo expression and function of B cell CD154 remain unclear and therefore were examined.
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases

    B Cell Checkpoints in Autoimmune Rheumatic Diseases

    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
  • The Role of the Immune Checkpoint Modulator OX40 and Its Ligand in NK Cell Immunosurveillance and Acute Myeloid Leukemia

    The Role of the Immune Checkpoint Modulator OX40 and Its Ligand in NK Cell Immunosurveillance and Acute Myeloid Leukemia

    1 The role of the immune checkpoint modulator OX40 and its ligand in NK cell 2 immunosurveillance and acute myeloid leukemia 3 Running title: OX40-OX40L in NK cell immunosurveillance 4 Keywords: OX40, AML, NK cells, immunotherapy, checkpoint 5 Tina Nuebling*1, Carla Emilia Schumacher*1,2, Martin Hofmann3, Ilona Hagelstein1, Benjamin Joachim 6 Schmiedel1, Stefanie Maurer1, Birgit, Federmann4, Kathrin Rothfelder1, Malte Roerden2, Daniela Dörfel1,2, 7 Pascal Schneider5, Gundram Jung3, Helmut Rainer Salih1,2 8 1 9 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German 10 Cancer Research Center (DKFZ), Heidelberg, Germany 2 11 Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany 3 12 Department of Immunology, Eberhard Karls University, Tuebingen, Germany 13 4 Department of Pathology, Eberhard Karls University, Tuebingen, Germany 14 5 Department of Biochemistry, Epalinges, Switzerland 15 16 *these authors contributed equally to this work 17 18 Corresponding Author: 19 Helmut R. Salih, M.D. 20 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German 21 Cancer Research Center (DKFZ) 22 Department of Hematology and Oncology, Eberhard Karls University 23 Otfried-Mueller Str. 10, 72076 Tuebingen, Germany 24 Phone: +49-7071-2983275; Fax: +49-7071-293671; Email: [email protected] 25 26 Funding: Supported by grants from the Deutsche Forschungsgemeinschaft (NU341/1-1, SA1360/7-3, 27 SFB685, project A07), Deutsche Krebshilfe (projects 111828 and 111134). PS is supported by grants from 28 the Swiss National Science Foundation. 29 Conflict-of-interest disclosure: The authors declare no potential conflicts of interest. 30 31 32 Text word count: 4347; Abstract word count: 238 33 5 figures, 2 tables, 4 supplementary figures 34 References: 50 1 35 Abstract 36 The TNF receptor family member OX40 promotes activation and proliferation of T cells, which 37 fuels present attempts to modulate this immune checkpoint to reinforce anti-tumor immunity.
  • (Blys) on Diabetes-Related Periodontitis

    (Blys) on Diabetes-Related Periodontitis

    ORIGINAL RESEARCH Immunology Preliminary findings on the possible role of B-lymphocyte stimulator (BLyS) on diabetes-related periodontitis Marx Haddley Ferreira Abstract: The possible role of B-cell growth and differentiation- DRUMOND(a) related cytokines on the pathogenesis of diabetes-related periodontitis Luciano Eduardo PUHL(a) has not been addressed so far. The aim of this study was to evaluate Poliana Mendes DUARTE(b) the effects of diabetes mellitus (DM) on the gene expression of Tamires Szeremeske de proliferation-inducing ligand (APRIL) and B-lymphocyte stimulator MIRANDA(c) (BLyS), two major cytokines associated to survival, differentiation Juliana Trindade and maturation of B cells in biopsies from gingival tissue with CLEMENTE-NAPIMOGA(a) periodontitis. Gingival biopsies were obtained from subjects with Daiane Cristina PERUZZO(a) periodontitis (n = 17), with periodontitis and DM (n = 19) as well as Elizabeth Ferreira MARTINEZ(a) from periodontally and systemically healthy controls (n = 10). Gene Marcelo Henrique NAPIMOGA(a) expressions for APRIL, BLyS, RANKL, OPG, TRAP and DC-STAMP were evaluated using qPCR. The expressions APRIL, BLyS, RANKL, (a) Faculdade São Leopoldo Mandic, Instituto OPG, TRAP and DC-STAMP were all higher in both periodontitis de Pesquisas São Leopoldo Mandic, groups when compared to the control group (p < 0.05). Furthermore, Campinas, SP, Brazil. the expressions of BLyS, TRAP and RANKL were significantly higher (b) University of Florida, College of Dentistry, in the subjects with periodontitis and DM when compared to those Department of Periodontology, Gainesville, FL, USA. with periodontitis alone (p < 0.05). The mRNA levels of BLyS correlated positively with RANKL in the subjects with periodontitis and DM (c) Guarulhos University, Dental Research Division, Department of Periodontology, São (p < 0.05).
  • Multimeric Forms of 4-1BBL As Stimulators of T Cells for Adoptive Immunotherapy

    Multimeric Forms of 4-1BBL As Stimulators of T Cells for Adoptive Immunotherapy

    Kornbluth et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P246 http://www.immunotherapyofcancer.org/content/2/S3/P246 POSTERPRESENTATION Open Access Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy Richard S Kornbluth1*, Victoria Snarsky1, Geoffrey W Stone2 From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014 Members of the TNF SuperFamily of ligands (TNFSFs) Authors’ details 1Multimeric Biotherapeutics, Inc., La Jolla, CA, USA. 2University of Miami, have significant potential as immuno-oncology therapeu- Miller School of Medicine, Miami, FL, USA. tic agents. The TNFSFs are trimeric membrane proteins that can be cleaved into soluble single trimers. While Published: 6 November 2014 the soluble single trimers can be easily prepared and studied, they have little or no activity in vivo. This defi- ciency is caused by the need to cluster their cognate doi:10.1186/2051-1426-2-S3-P246 Cite this article as: Kornbluth et al.: Multimeric forms of 4-1BBL as receptors in the plane of the membrane in order to stimulators of T cells for adoptive immunotherapy. Journal for induce a supramolecular signaling complex on the cyto- ImmunoTherapy of Cancer 2014 2(Suppl 3):P246. plasmic side of the plasma membrane. For the TNFSF ligands, this requires that they be used as many-trimer multimers that mimic the natural expression of many trimers on the surface of stimulating cells. To meet this need, we prepared fusion proteins comprised of the extracellular domains of TNFSF ligands joined to a nat- ural protein that provides a multimerization scaffold.
  • Belongs to the TNF Family a New Class of Reverse Signaling

    Belongs to the TNF Family a New Class of Reverse Signaling

    A New Class of Reverse Signaling Costimulators Belongs to the TNF Family Mingyi Sun and Pamela J. Fink This information is current as J Immunol 2007; 179:4307-4312; ; of September 27, 2021. doi: 10.4049/jimmunol.179.7.4307 http://www.jimmunol.org/content/179/7/4307 References This article cites 85 articles, 38 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/179/7/4307.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on September 27, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS A New Class of Reverse Signaling Costimulators Belongs to the TNF Family Mingyi Sun and Pamela J. Fink1 Recent evidence shows that many molecules of the TNF still remains unclear (7). The N-terminal cytoplasmic domains family serve as counter-receptors, inducing costimulation of most TNF family members are conserved across species but through reverse signals in addition to delivering signals not between family members, suggesting that the intracellular through their respective TNF receptors.
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency

    Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency

    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.